UNSPSC 51262910: Bopindolol hydrogen malonate

This classification denotes an adrenergic beta-antagonist with the molecular formula C23H28N2O3.C3H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3UWR70991, chemically known as propanedioic acid, compd. with (+/-)-2-((1,1-dimethylethyl)amino)-1-(((2-methyl-1h-indol-4-yl)oxy)methyl)ethyl benzoate (1:1), but more generally known as bopindolol hydrogen malonate, which bears US NIH Compound Identifier 636368.

European Medicines Agency schedules bopindolol hydrogen malonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05873MIG. Most nations, for tariff purposes, schedule bopindolol hydrogen malonate under HS 29339990. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)(C)C)OC(=O)C3CCCCC3.C(C(=O)O)C(=O)O.

UNSPSC 51262910 Bopindolol hydrogen malonate is a Commodity code that nominally covers a specific pharmaceutical compound, yet the recent state and local opportunities tagged to it show little alignment with the code's narrow scope. The single directly relevant solicitation — Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems — addresses naloxone procurement (a different active pharmaceutical ingredient used for opioid overdose reversal) and drug deactivation equipment rather than bopindolol. The second tagged opportunity, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription fulfillment, involves pharmacy benefit program strategy and vendor capability assessment but does not name a specific pharmaceutical product. State and local procurement offices appear to use this code inconsistently or as a catch-all for pharmaceutical procurement activity that does not fit narrower commodity categories, creating a mismatch between the code's defined product and the actual buying activity.

The issuing bodies soliciting under this code span state health and human services agencies and county public-health departments, with recent activity concentrated in Florida and Texas. Seminole County's naloxone procurement (IFB, response due July 26, 2023) calls for 1,900 units annually with quarterly deliveries to the county community health building, subject to E-Verify compliance, drug-free workplace certification, and a two-year initial term with one-year renewal option. The Texas HHS RFI (posted April 3, 2026, response due April 3, 2026) represents exploratory procurement phase activity designed to gather vendor intelligence on direct pharmaceutical contracting models before formal solicitation. Given the code's narrow pharmaceutical focus and the apparent tagging misalignment, firms targeting this code should monitor state health department and county health authority RFPs and RFQs rather than rely on UNSPSC 51262910 alone to surface relevant opportunities.